Business
Charlotte's Web Appoints Marcel Bonn-Miller Ph.D. as Chief Scientific Officer
Charlotte's Web Appoints Marcel Bonn-Miller Ph.D. as Chief Scientific Officer Canada Ne...
About this update from Charlotte's Web Holdings, Inc.
[{"type":"text","content":"\n \n \n \n Charlotte's Web Appoints Marcel Bonn-Miller Ph.D. as Chief Scientific Officer\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Dr. Bonn-Miller to lead clinical science supporting product development, CBD regulation, alternative botanical wellness\n \n \n \n \n \n DENVER\n \n \n ,\n \n \n March 8, 2023\n \n \n /CNW/ - (TSX: CWEB) (OTCQX: CWBHF)\n \n Charlotte's\n \n Web Holdings, Inc. (\"\n \n Charlotte's\n \n Web\" or the \"Company\"), the market leader in cannabidiol (\"CBD\")\n \n hemp extract wellness products\n \n has appointed Dr.\n \n Marcel Bonn-Miller\n \n , Ph.D. as its Chief Scientific Officer.\n \n \n \n \n \n \n \n \n \n Dr. Bonn-Miller brings more than two decades of cannabis/cannabinoid research experience to\n \n Charlotte's\n \n Web. Prior to joining\n \n Charlotte's\n \n Web, he served four years at Canopy Growth Corporation, most recently as Vice-President of Human and Animal Research. In addition to his work at Canopy Growth Corporation, Dr. Bonn-Miller has held positions as Director of Cannabinoid Research at Zynerba Pharmaceuticals, Adjunct Assistant Professor at the\n \n University of Pennsylvania\n \n Perelman School of Medicine, and Health Science Specialist at the Department of Veterans Affairs in\n \n Palo Alto, California\n \n .\n \n \n In his new role, Dr. Bonn-Miller will lead the Company's R&D portfolio, including new product development, pre-clinical and clinical research, scientific regulatory support, and alternative botanical wellness. He will build upon the Company's existing safety and toxicology data and interface with the FDA's science teams to support regulatory pathways for hemp CBD extracts.\n \n \n \"The known and potential therapeutic effects of the hemp plant and its compounds are extraordinary,\" said Dr. Bonn-Miller. \"A natural therapeutic from such a complex plant requires exceptional consistency in genetics and cultivation. This is where\n \n Charlotte's\n \n Web has uniquely excelled and provides an unprecedented opportunity ...